Clinical trial
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in…
NCT00397761 · Medstar Health Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00397761 |
|---|---|
| Title | Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer |
| Official title | Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer |
| Lead sponsor | Medstar Health Research Institute, Other |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | capecitabine, paclitaxel albumin-stabilized nanoparticle formulation, neoadjuvant therapy |
| Enrollment | 0 |
| Start date | Jul 1, 2006 |
| First posted | Nov 9, 2006 |
| Last update posted | Feb 17, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: